ArticleJournal of fungi (Basel, Switzerland)2021
In Vitro Characterization of Twenty-One Antifungal Combinations against Echinocandin-Resistant and -Susceptible
Article in Journal of fungi (Basel, Switzerland), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 29 citations in OpenAlex.
- Synergistic activity of caspofungin and posaconazole againstMicrobiology spectrum · 2026Article
- Article
- In Vitro Evaluation of 5-Fluorouridine as an Adjuvant to Antifungal Drugs and Molecular Insights into Resistance to This Compound inInternational journal of molecular sciences · 2025Article
- Aspergillosis: A comprehensive review of pathogenesis, drug resistance, and emerging therapeutics.Journal of food and drug analysis · 2025Review
- Drug analysis of a fatal case of bloodstream infection combined with urinary tract infection due to echinocandin-resistantIDCases · 2025Article
- Biomimetic Antifungal Materials: Countering the Challenge of Multidrug-Resistant Fungi.Biomimetics (Basel, Switzerland) · 2024Review
- Antifungal activity of indolicidin-derived peptide In-58 againstFrontiers in medicine · 2024Article
- Antifungal Resistance and Genotyping of ClinicalJournal of fungi (Basel, Switzerland) · 2023Article
- Article
- Critical appraisal beyond clinical guidelines for intraabdominal candidiasis.Critical care (London, England) · 2023Review
- Antimicrobial Peptides: Avant-Garde Antifungal Agents to Fight against Medically ImportantPharmaceutics · 2023Review
- Echinocandins - structure, mechanism of action and use in antifungal therapy.Journal of enzyme inhibition and medicinal chemistry · 2022Review
- Synergistic Interaction of Caspofungin Combined with Posaconazole againstAntibiotics (Basel, Switzerland) · 2022Article
- Prevalence of Antifungal Resistance, Genetic Basis of Acquired Azole and Echinocandin Resistance, and Genotyping of Candida krusei Recovered from an International Collection.Antimicrobial agents and chemotherapy · 2022Article
- Fungal Biofilms as a Valuable Target for the Discovery of Natural Products That Cope with the Resistance of Medically Important Fungi-Latest Findings.Antibiotics (Basel, Switzerland) · 2021Review
- Fungicidal Activity of a Safe 1,3,4-Oxadiazole Derivative AgainstPathogens (Basel, Switzerland) · 2021Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 2 countries.
Funding
Abstract
This study was designed to analyze the interaction of 21 antifungal combinations consisting of seven major antifungal agents against 11 echinocandin- susceptible and six-resistant
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.